The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Abstract
The novel coronavirus causing the COVID-19 pandemic, SARS-CoV-2, gains entry to pulmonary cells after binding to membrane ACE2 [1]. This enzyme is a homologue of ACE1, which converts angiotensin I to angiotensin II, is active in cardiovascular control, can be an element in cardiovascular disease, and is therapeutically targeted in hypertension and heart failure, using ACE1 inhibitors such as enalapril and lisinopril. The biology and therapeutic potential of ACE2 is much less clear. Commonly, it is viewed in the cardiovascular sphere as somehow antagonistic to the adverse effects of ACE1, and beneficial. This remains not well worked out, and currently there are no specific cardiovascular therapies involving ACE2. One action of ACE2 is to enzymatically cleave angiotensin II to angiotensin (1–7). Given the importance of ACE2 in SARS-CoV-2 entry to cells, cardiovascular illnesses or cardiovascular drugs, which increase ACE2 expression, and there are several important instances of this [2–6], may perhaps increase human SARS-CoV-2 infectivity and illness severity. We understand that hypertension increases the severity of COVID-19 illness. This is surprising, on two counts. First, ACE2 expression typically is reduced in hypertension models, and second, hypertension does not appear to impact other infections. One of us (M.E.), a cardiologist with more than four decades of hypertension tertiary care experience, cannot recall one of his patients ever dying from an infection. Infection predisposition in diabetes is evident, but not in hypertension. Perhaps in the COVID-19 pandemic, a new infection risk is arising from special properties of some antihypertensive drugs? Angiotensin receptor-blocker (ARB) drugs, now becoming the most commonly used antihypertensive drug class, typically increase ACE2 expression, often very substantially (perhaps two-fold to five-fold) [3–6]. This is sufficiently clear to have sometimes been used in marketing for ARBs, with a claim by pharmaceutical companies that this provides specific benefit in cardiovascular diseases. Perhaps, although this is unproven. With SARS-CoV-2 infection increased ACE2 expression very definitely would not be beneficial, and could be adverse. Increased ACE2 expression with angiotensin receptor blockers has been demonstrated in the kidneys and heart [4–6] but has not been tested to our knowledge, and this is now necessary, in the lungs. Reducing ACE2 expression as a therapeutic principle for COVID-19 control? How might angiotensin receptor blockers increase ACE2 expression. Plasma levels of angiotensin II increase with ARB dosing [7–10]. Angiotensin II is the known substrate for ACE2. Perhaps this is a case of substrate availability increasing the expression of the linked enzyme. This is hypothetical, but could be used as a framework to consider alternative drugs to ARBs during the COVID-19 pandemic. Both ACE1 inhibitors and beta-adrenergic blockers reduce plasma concentrations of angiotensin II, the ACE2 substrate, for ACE1 inhibitors by reducing cleavage of angiotensin I to angiotensin II, and with beta-blockers by reducing release of renin from the kidneys. This might suggest they are potentially suitable replacements and preferred, because they potentially reduce ACE2 expression. Calcium channel blockers, another antihypertensive class mainstay, are neutral concerning angiotensin II availability, and potentially suitable. Diuretics and mineralocorticoid antagonists increase angiotensin II production, because of body sodium losses, which in the context of a COVID-19 pandemic might be adverse; sodium loading does reduce ACE2 expression. But in truth, inferences of ACE2 expression changes during antihypertensive dosing from known changes in angiotensin availability may possibly not be valid. The crucial point is that angiotensin receptor blocker drugs increase ACE2 expression remarkably, which is a significant demerit, emphasized by the fact that one favoured path of vaccine development is immunological antagonism of the ACE2 binding site for the SARS-CoV-2 virus spike protein. We have presented the hypothesis that prescribing of angiotensin receptor-blocking drugs during the COVID-19 pandemic might possibly be harmful, and suggested that other antihypertensive drug classes are preferred. We hope that the clinical data base from the pandemic so far could provide sufficient detail on hypertension diagnosis and antihypertensive drug prescribing to test our hypothesis. If the hypothesis was confirmed, how might this be applied clinically? One application would be in those SARS-CoV-2-infected patients who have a blood pressure rise during their acute illness, which has been noted. Any current dosing of ARB drugs should not be escalated, or new ARB therapy initiated. Perhaps ARBs currently prescribed should be entirely replaced in the acute illness by other antihypertensives as needed. The caveat here is that the rate at which excess ACE2 protein would disappear from
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Ferrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 713
Ishiyama, Y., Gallagher, P. E., Averill, D. B., Tallant, E. A., Brosnihan, K. B., & Ferrario, C. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000124667.34652.1a · Cited by 564
Zisman, L. S., Keller, R. S., Weaver, B., Lin, Q., Speth, R., Bristow, M. R., & Canver, C. C. (2003) · Circulation · doi:10.1161/01.cir.0000094734.67990.99 · Cited by 308
Gottlieb, S. S., Dickstein, K., Fleck, E., Kostis, J., Levine, T. B., LeJemtel, T., & DeKock, M. (1993) · Circulation · doi:10.1161/01.cir.88.4.1602 · Cited by 291
ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
Lee, I. T., Nakayama, T., Wu, C.-T., Goltsev, Y., Jiang, S., Gall, P. A., Liao, C.-K., Shih, L.-C., Schürch, C. M., McIlwain, D. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19145-6 · Cited by 263
Jessup, J. A., Gallagher, P. E., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Chappell, M. C., & Ferrario, C. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00061.2006 · Cited by 128
MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides
Gallagher, P. E., Ferrario, C. M., & Tallant, E. A. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00145.2008 · Cited by 100
Böhm, M., Frey, N., Giannitsis, E., Sliwa, K. S., & Zeiher, A. M. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01656-3 · Cited by 81
Cited by
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Acute kidney injury in patients hospitalized with COVID-19
Hirsch, J. S., Ng, J. H., Ross, D. W., Sharma, P., Shah, H. H., Barnett, R. L., Hazzan, A. D., Fishbane, S., Jhaveri, K. D., Abate, M., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.05.006 · Cited by 1,523
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237
“[76] [77] [78] [79] [80] [81] [82] [83] [84] Several Scientific Societies and various experts in this area expressed the position that discontinuation of these drugs is not justified by evidence and could be dangerous.”
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
Mancia, G., Rea, F., Ludergnani, M., Apolone, G., & Corrao, G. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006923 · Cited by 1,073
Metadata
- Authors
- Esler, M., & Esler, D.
- Venue
- Journal of Hypertension
- Published
- 2020-05
- Volume
- 38
- Issue
- 5
- Pages
- 781-782
- ISSN
- 0263-6352 (ISSN-L)
- 1473-5598
- OpenAlex
- W3012285389
- Cited by
- 296
- References
- 14
- FWCI
- 39.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? https://app.cochat.ai/papers/10.1097/hjh.0000000000002450
- The paper
- Esler, M., & Esler, D. (2020). Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000002450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.